With combo needing 300 patients safety initially at 350mg and then money for the BLA, I believe their need for cash over the last two years was greater than their ability to find demand with investors. It seems almost half of the 200M they have raised since 2012 for leronlimab has been raised since last year. Raising $100M when the stock price is 50c-75c is a big feat.

That should change once the secure funding, reducing the cash burn, and then with tnbc injection, the BLA, and mono pivotal, increasing the investor demand... fixing the problem on both ends.